Spinal Cord Injury Therapeutics Market, by Injury Type (Complete Spinal Cord Injury and Incomplete Spinal Cord Injury), by Drug Type (Corticosteroids, Muscle Relaxants and Anti-spastic drugs, Non-steroidal Anti-inflammatory drugs (NSAIDs), Anti-depressant

Spinal Cord Injury Therapeutics Market, by Injury Type (Complete Spinal Cord Injury and Incomplete Spinal Cord Injury), by Drug Type (Corticosteroids, Muscle Relaxants and Anti-spastic drugs, Non-steroidal Anti-inflammatory drugs (NSAIDs), Anti-depressants, Anticonvulsants, and  Others), by Application (Autonomic Dysreflexia (AD), Spasticity & Inflammation, Pain Management, and Depression), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

The global spinal cord injury therapeutics market comprises therapeutics used for the treatment of spinal cord injury such as corticosteroids, non-steroidal anti-inflammatory drugs (NSAID’S), muscle relaxants, and anti-depressants. There are two types of spinal cord injuries including complete spinal cord injury and incomplete spinal cord injury and various causes of spinal cord injuries include brain injury, trauma, loss of blood supply to spinal cord, and compression in spinal cord due to tumor or infections.
Market Dynamics
Key players are focusing on product approvals to strengthen their position in the global spinal cord injury therapeutics market. For instance, in September 2021, AbbVie Inc., received an orphan drug and fast track designation from the U.S. Food and Drug Administration for Elezanumab, an investigational monoclonal antibody RGMa inhibitor for the treatment of spinal cord injury.
Key features of the study:
This report provides in-depth analysis of the global spinal cord injury therapeutics market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global spinal cord injury therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie Inc., Pfizer Inc., Dr. Reddy's Laboratories Ltd., Zydus Cadila, ReNetX Bio, Inc., InVivo Therapeutics Holdings, Lineage Cell Therapeutics, Inc., Kringle Pharma, Inc., Acorda Therapeutics, Inc., Bioaxone Biosciences, Inc., RespireRx Pharmaceuticals Inc., NervGen, Rising Pharmaceuticals, Inc., ScieGen Pharmaceuticals, Inc., MSN Laboratories Private Limited, and Lannett Co Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global spinal cord injury therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global spinal cord injury therapeutics market
Detailed Segmentation:
Global Spinal Cord Injury Therapeutics Market, By Injury Type:
Complete Spinal Cord Injury
Incomplete Spinal Cord Injury
Global Spinal Cord Injury Therapeutics Market, By Drug Type:
Corticosteroids
Muscle Relaxants and Anti-spastic drugs
Non-steroidal Anti-inflammatory drugs (NSAIDs)
Anti-depressants
Anticonvulsants
Others
Global Spinal Cord Injury Therapeutics Market, By Application:
Autonomic Dysreflexia (AD)
Spasticity & Inflammation
Pain Management
Depression
Global Spinal Cord Injury Therapeutics Market, By Route of Administration:
Oral
Intravenous
Global Spinal Cord Injury Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Spinal Cord Injury Therapeutics Market, By Region:
North America
By Injury Type
Complete Spinal Cord Injury
Incomplete Spinal Cord Injury
By Drug Type
Corticosteroids
Muscle Relaxants and Anti-spastic drugs
Non-steroidal Anti-inflammatory drugs (NSAIDs)
Anti-depressants
Anticonvulsants
Others
By Application
Autonomic Dysreflexia (AD)
Spasticity & Inflammation
Pain Management
Depression
By Route of Administration
Oral
Intravenous
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Injury Type
Complete Spinal Cord Injury
Incomplete Spinal Cord Injury
By Drug Type
Corticosteroids
Muscle Relaxants and Anti-spastic drugs
Non-steroidal Anti-inflammatory drugs (NSAIDs)
Anti-depressants
Anticonvulsants
Others
By Application
Autonomic Dysreflexia (AD)
Spasticity & Inflammation
Pain Management
Depression
By Route of Administration
Oral
Intravenous
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Injury Type
Complete Spinal Cord Injury
Incomplete Spinal Cord Injury
By Drug Type
Corticosteroids
Muscle Relaxants and Anti-spastic drugs
Non-steroidal Anti-inflammatory drugs (NSAIDs)
Anti-depressants
Anticonvulsants
Others
By Application
Autonomic Dysreflexia (AD)
Spasticity & Inflammation
Pain Management
Depression
By Route of Administration
Oral
Intravenous
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Injury Type
Complete Spinal Cord Injury
Incomplete Spinal Cord Injury
By Drug Type
Corticosteroids
Muscle Relaxants and Anti-spastic drugs
Non-steroidal Anti-inflammatory drugs (NSAIDs)
Anti-depressants
Anticonvulsants
Others
By Application
Autonomic Dysreflexia (AD)
Spasticity & Inflammation
Pain Management
Depression
By Route of Administration
Oral
Intravenous
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Injury Type
Complete Spinal Cord Injury
Incomplete Spinal Cord Injury
By Drug Type
Corticosteroids
Muscle Relaxants and Anti-spastic drugs
Non-steroidal Anti-inflammatory drugs (NSAIDs)
Anti-depressants
Anticonvulsants
Others
By Application
Autonomic Dysreflexia (AD)
Spasticity & Inflammation
Pain Management
Depression
By Route of Administration
Oral
Intravenous
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Injury Type
Complete Spinal Cord Injury
Incomplete Spinal Cord Injury
By Drug Type
Corticosteroids
Muscle Relaxants and Anti-spastic drugs
Non-steroidal Anti-inflammatory drugs (NSAIDs)
Anti-depressants
Anticonvulsants
Others
By Application
Autonomic Dysreflexia (AD)
Spasticity & Inflammation
Pain Management
Depression
By Route of Administration
Oral
Intravenous
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Teva Pharmaceutical Industries Ltd.*
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
AbbVie Inc.
Pfizer Inc.
Reddy's Laboratories Ltd.
Zydus Cadila
ReNetX Bio, Inc.
InVivo Therapeutics Holdings
Lineage Cell Therapeutics, Inc.
Kringle Pharma, Inc.
Acorda Therapeutics, Inc.
Bioaxone Biosciences, Inc.
RespireRx Pharmaceuticals Inc.
NervGen
Rising Pharmaceuticals, Inc.
ScieGen Pharmaceuticals, Inc.
MSN Laboratories Private Limited
Lannett Co Inc.
“*” marked represents similar segmentation in other categories in the respective section.